
Opinion|Videos|October 7, 2024
ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections
Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
- Comparing the two clinical trials, what were some significant differences between them?
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contagion Live
1
Public Health Wake-Up Call: Will the US Lose Measles Elimination Status?
2
Recent Florida Cases of Chikungunya Linked to Cuba Travelers, Reminder Vector-Borne Illness is Still Circulating
3
CDC Adopts Individual-Based Decision-Making for Hepatitis B Vaccine for Infants
4
Study Shows Gut-Restricted Synthetic Bile Acid Neutralizes C difficile Toxin B
5



















































































































































































































































































